Based on the current literature, rare harmful variants in SOX17 account for about 1.9%–6.3% of children with PAH, in particular with PAH-CHD (Levy et al., 2016; Zhu et al., 2018b; Zhu et al., 2019). Here, SOX17 is linked to pulmonary arterial hypertension.